In yesterday’s Wall Street session, Baxter International Inc. (NYSE:BAX) shares traded at $40.96, down -1.66% from the previous session.
As of this writing, 19 analysts cover Baxter International Inc. (NYSE:BAX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $58.00 and a low of $45.00, we find $50.00. Given the previous closing price of $41.65, this indicates a potential upside of 20.05 percent. BAX stock price is now -4.71% away from the 50-day moving average and -15.57% away from the 200-day moving average. The market capitalization of the company currently stands at $20.67B.
There are 12 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $50.43 as their price target over the next twelve months.
In other news, STROUCKEN ALBERT P L, Director sold 3,930 shares of the company’s stock on Mar 20. The stock was sold for $147,454 at an average price of $37.52. Upon completion of the transaction, the Director now directly owns 36,835 shares in the company, valued at $1.51 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 21, SVP, Chief Quality Officer Kunzler Jacqueline sold 3,813 shares of the business’s stock. A total of $154,426 was realized by selling the stock at an average price of $40.50. This leaves the insider owning 16,725 shares of the company worth $0.69 million. Insiders disposed of 95,287 shares of company stock worth roughly $3.9 million over the past 1 year. A total of 0.24% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BAX stock. A new stake in Baxter International Inc. shares was purchased by ARTISAN PARTNERS LIMITED PARTNERSHIP during the first quarter worth $149,511,000. POINT72 ASSET MANAGEMENT, L.P. invested $148,526,000 in shares of BAX during the first quarter. In the first quarter, CAMBER CAPITAL MANAGEMENT LP acquired a new stake in Baxter International Inc. valued at approximately $122,880,000. PARNASSUS INVESTMENTS, LLC acquired a new stake in BAX for approximately $85,472,000. ORBIMED ADVISORS LLC purchased a new stake in BAX valued at around $63,980,000 in the second quarter. In total, there are 1,340 active investors with 89.50% ownership of the company’s stock.
Tuesday morning saw Baxter International Inc. (NYSE: BAX) opened at $41.50. During the past 12 months, Baxter International Inc. has had a low of $37.35 and a high of $73.63. As of last week, the company has a debt-to-equity ratio of 2.79, a current ratio of 1.70, and a quick ratio of 1.10. The fifty day moving average price for BAX is $43.02 and a two-hundred day moving average price translates $48.41 for the stock.
The latest earnings results from Baxter International Inc. (NYSE: BAX) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.59, beating analysts’ expectations of $0.49 by 0.1. This compares to $0.14 EPS in the same period last year. The net profit margin was -16.30% and return on equity was -37.70% for BAX. The company reported revenue of $3.65 billion for the quarter, compared to $3.71 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.56 percent. For the current quarter, analysts expect BAX to generate $3.8B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 07/03/2023. Investors who held shares on 06/02/2023 were paid a $0.29 dividend. On an annualized basis, this represents a $1.16 dividend and a 2.83% percent yield. There was an ex-dividend date of 06/01/2023 for this dividend.
Baxter International Inc.(BAX) Company Profile
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.